Janux Therapeutics JANX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's cash & equivalents?
- Janux Therapeutics (JANX) reported cash & equivalents of $51.83M in Q1 2026.
- How has Janux Therapeutics's cash & equivalents changed year-over-year?
- Janux Therapeutics's cash & equivalents decreased by 29.7% year-over-year, from $73.74M to $51.83M.
- What is the long-term trend for Janux Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Janux Therapeutics's cash & equivalents has grown at a 46.3% compound annual growth rate (CAGR), from $7.81M to $52.33M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.